NuVasive wins FDA approval for PCM spine implant
NuVasive says the FDA granted pre-market approval to its PCM cervical disc system, sending shares up on Wall Street today.
The San Diego-based medical device company said the implant is designed to preserve motion in the cervical spine, in lieu of a standard fusion procedure. The FDA nod came after a 403-patient investigation device exemption trial, according to NuVasive.
NUVA shares were trading at $14.23 as of about 12:30 p.m. today, up 2.3%.